For instance, we identified mutations in STAG2 as a high-confidence biomarker of poor prognosis in glioma, and we found that STAG2-mutant gliomas were exquisitely sensitive to treatment with the PARP inhibitor olaparib (Figure 5A). The gene discussed is STAG2; the disease is glioma.